TNIK and cancer: In BET bromodomain inhibitor JQ1‐resistance HCT116 cells, which showed high resistance to various anti‐cancer drugs, including cisplatin, TNIK (TRAF2 and NCK‐interacting protein kinase) was a regulator of Wnt/β‐catenin signaling and transactivate cyclin D1 (CCND1) and cyclin E1 (CCNE1) [14].